← Leaderboards
Shou-Jiang Gao
University Of Texas Hlth Science Center
$25,960,652
Attributed
$26,177,212
Total exposure
19
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,177,212 · 19
By mechanism
R01$25,351,618 · 12
R21$433,120 · 1
M01$346,590 · 3
P30$34,500 · 1
P41$11,384 · 2
Top collaborators
- Yufei Huang2 shared
Others in their field
Top investigators on “Human Herpesvirus 8”
- David Heimbrook · Leidos Biomedical Research, Inc.$188,989,000
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Leonard Freedman · Leidos Biomedical Research, Inc.$65,587,215
- Jae U Jung · Cleveland Clinic Lerner Com-Cwru$44,754,023
- Scott W Wong · Oregon Health And Science University$28,229,656
- Blossom A Damania · University Of North Carolina Chapel Hill$27,475,432
Research focus
Human Herpesvirus 8Kaposi SarcomaMalignant NeoplasmsMediatingPathogenesisTumorAcquired Immunodeficiency SyndromeInnovationPathway InteractionsViralCellsMorbidity - Disease RateInsightBaseHerpesviridae InfectionsTumorigenesisPreventionSocietiesInfectionTherapeutic TargetMulticentric Angiofollicular Lymphoid HyperplasiaMolecularProteinsPrimary Effusion Lymphoma
Grant awards (88)
Impact of microbiota on AIDS-Kaposiâs sarcoma development and therapy$785,019
R01 · FY2025 · CA · contact PI
METTL16 and S-adenosylmethionine cycle in KSHV infection$674,661
R01 · FY2025 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$569,633
R01 · FY2025 · CA · contact PI
Citrulline-urea cycle in KSHV cellular transformation$526,066
R01 · FY2025 · CA · contact PI
Regulation of KSHV replication by N6-methyladenosine (m6A)$339,863
R01 · FY2025 · CA · contact PI
Novel geometric deep learning models for tissue structure-aware spatial expression representations from spatially resolved single-cell transcriptomics data$234,370
R21 · FY2025 · GM
Impact of microbiota on AIDS-Kaposiâs sarcoma development and therapy$784,127
R01 · FY2024 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$569,871
R01 · FY2024 · CA · contact PI
Citrulline-urea cycle in KSHV cellular transformation$526,066
R01 · FY2024 · CA · contact PI
Regulation of KSHV replication by N6-methyladenosine (m6A)$344,531
R01 · FY2024 · CA · contact PI
Novel geometric deep learning models for tissue structure-aware spatial expression representations from spatially resolved single-cell transcriptomics data$198,750
R21 · FY2024 · GM
Regulation of KSHV replication by N6-methyladenosine (m6A)$4,668
R01 · FY2024 · CA · contact PI
Impact of microbiota on AIDS-Kaposiâs sarcoma development and therapy$793,089
R01 · FY2023 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$584,851
R01 · FY2023 · CA · contact PI
Citrulline-urea cycle in KSHV cellular transformation$540,484
R01 · FY2023 · CA · contact PI
Regulation of KSHV replication by N6-methyladenosine (m6A)$339,863
R01 · FY2023 · CA · contact PI
Regulation of KSHV replication by N6-methyladenosine (m6A)$239,052
R01 · FY2023 · CA · contact PI
Regulation of KSHV replication by N6-methyladenosine (m6A)$339,863
R01 · FY2022 · CA · contact PI
Regulation of KSHV replication by N6-methyladenosine (m6A) - Diversity Supplement$97,654
R01 · FY2022 · CA · contact PI
Cell model for KSHV Infection and Genetic Manipulation$391,250
R01 · FY2021 · CA · contact PI
Regulation of KSHV replication by N6-methyladenosine (m6A)$334,965
R01 · FY2021 · CA · contact PI
KSHV microRNAs in tumor invasion and angiogenesis$189,697
R01 · FY2021 · CA · contact PI
Cell model for KSHV Infection and Genetic Manipulation$391,250
R01 · FY2020 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$372,873
R01 · FY2020 · CA · contact PI
KSHV microRNAs in tumor invasion and angiogenesis$189,697
R01 · FY2020 · CA · contact PI
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES$391,250
R01 · FY2019 · DE · contact PI
Cell model for KSHV Infection and Genetic Manipulation$379,512
R01 · FY2019 · CA · contact PI
Targeting KSHV malignancies and persistent infection$347,253
R01 · FY2019 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$342,391
R01 · FY2019 · CA · contact PI
KSHV microRNAs in tumor invasion and angiogenesis$189,697
R01 · FY2019 · CA · contact PI
Cancer Virology Program (Project-002)$34,500
P30 · FY2019 · CA · contact PI
Cell model for KSHV Infection and Genetic Manipulation$391,250
R01 · FY2018 · CA · contact PI
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES$391,250
R01 · FY2018 · DE · contact PI
Targeting KSHV malignancies and persistent infection$357,994
R01 · FY2018 · CA · contact PI
KSHV microRNAs in tumor invasion and angiogenesis$189,697
R01 · FY2018 · CA · contact PI
Targeting KSHV malignancies and persistent infection$19,444
R01 · FY2018 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$1
R01 · FY2018 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$412,500
R01 · FY2017 · CA · contact PI
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES$412,500
R01 · FY2017 · DE · contact PI
Mechanism of KSHV-induced angiogenesis$391,875
R01 · FY2017 · CA · contact PI
Targeting KSHV malignancies and persistent infection$377,438
R01 · FY2017 · CA · contact PI
KSHV microRNAs in tumor invasion and angiogenesis$200,000
R01 · FY2017 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$162,546
R01 · FY2017 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$134,256
R01 · FY2017 · CA · contact PI
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES$412,500
R01 · FY2016 · DE · contact PI
Mechanism of KSHV-induced angiogenesis$391,875
R01 · FY2016 · CA · contact PI
Targeting KSHV malignancies and persistent infection$377,438
R01 · FY2016 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$304,095
R01 · FY2016 · CA · contact PI
HISTONE MODIFIERS IN ORAL KSHV INFECTION AND MALIGNANCIES$412,500
R01 · FY2015 · DE · contact PI
Mechanism of KSHV-induced angiogenesis$391,578
R01 · FY2015 · CA · contact PI
Targeting KSHV malignancies and persistent infection$377,247
R01 · FY2015 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$303,864
R01 · FY2015 · CA · contact PI
KSHV microRNAs in cellular transformation and tumorigenesis$201,171
R01 · FY2015 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$293,855
R01 · FY2014 · CA · contact PI
KSHV microRNAs in cellular transformation and tumorigenesis$194,642
R01 · FY2014 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$302,252
R01 · FY2013 · CA · contact PI
KSHV microRNAs in cellular transformation and tumorigenesis$200,052
R01 · FY2013 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$370,959
R01 · FY2012 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$329,252
R01 · FY2012 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$384,003
R01 · FY2011 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$253,108
R01 · FY2011 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$200,016
R01 · FY2011 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$95,986
R01 · FY2011 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$89,923
R01 · FY2011 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$29,764
R01 · FY2011 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$349,703
R01 · FY2010 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$308,138
R01 · FY2010 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$277,400
R01 · FY2010 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$48,411
R01 · FY2010 · CA · contact PI
Cell model for KSHV infection and genetic manipulation$361,641
R01 · FY2009 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$307,705
R01 · FY2009 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$277,400
R01 · FY2009 · CA · contact PI
Role of Epstein-Barr virus LMP1 in lymphoma$125,053
R01 · FY2009 · CA · contact PI
Role of Epstein-Barr virus LMP1 in lymphoma$93,674
R01 · FY2009 · CA · contact PI
Mechanism of KSHV-induced angiogenesis$27,176
R01 · FY2009 · CA · contact PI
CELL MODEL FOR KSHV INFECTION AND GENETIC MANIPULATION$3,309
P41 · FY2009 · RR · contact PI
Mechanism of KSHV-induced angiogenesis$307,100
R01 · FY2008 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$277,400
R01 · FY2008 · CA · contact PI
Regulation of KSHV infection and replication by MAPK pathways$76,713
R01 · FY2008 · CA · contact PI
ORAL KSHV (KAPOSI'S SARCOMA HERPES VIRUS) COMPLICATIONS IN HIV INFECTION$45,992
M01 · FY2008 · RR · contact PI
CELL MODEL FOR KSHV INFECTION AND GENETIC MANIPULATION$8,075
P41 · FY2008 · RR · contact PI
Cell Model for KSHV Infection and Genetic Manipulation$335,207
R01 · FY2007 · CA · contact PI
Oral KSHV Complications in HIV Infection$311,478
R01 · FY2007 · DE · contact PI
Regulation of KSHV infection and replication by MAPK pathways$277,400
R01 · FY2007 · CA · contact PI
ORAL KSHV (KAPOSI'S SARCOMA HERPES VIRUS) COMPLICATIONS IN HIV INFECTION$276,110
M01 · FY2007 · RR · contact PI
Cell Model for KSHV Infection and Genetic Manipulation$333,211
R01 · FY2006 · CA · contact PI
Oral KSHV Complications in HIV Infection$320,781
R01 · FY2006 · DE · contact PI
ORAL KSHV (KAPOSI'S SARCOMA HERPES VIRUS) COMPLICATIONS IN HIV INFECTION$24,488
M01 · FY2006 · RR · contact PI